

AMENDMENT TO THE CLAIMS

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1. (Currently Amended) Transdermal drug delivery system (TDS) comprising
 - a cover which is impermeable for the active ingredient,
 - a matrix containing oxybutynin as active ingredient and
 - a facultative release liner, wherein the matrix further comprises
 - an ~~Aloe Vera~~ *Aloe vera* extract,
 - a pressure sensitive adhesive and
 - a cross linking agent for the adhesive.
2. (Original) Transdermal drug delivery system according to claim 1, comprising racemic oxybutynin, R-oxybutynin, S-oxybutynin or desethyl-oxybutynin.
3. (Previously Presented) Transdermal drug delivery according to claim 1, wherein the pressure sensitive adhesive of the matrix is comprised of an acrylate based polymer, preferably a polymer based on an acrylate-vinyl acetate copolymer.
4. (Cancelled)
5. (Previously Presented) Transdermal drug delivery system according to claim 1, wherein the matrix comprises Ti-acetylacetone, Al-acetylacetone or polybutyl-titanate as crosslinking agent.
6. (Currently Amended) Transdermal drug delivery system according to claim 1, wherein the extracting agent of the ~~Aloe Vera~~ *Aloe vera*-extract is a vegetable oil, preferably soybean oil.
7. (Currently Amended) Transdermal drug delivery system according to claim 6, wherein the ~~Aloe Vera~~ *Aloe vera*-extract comprises 5 to 15 % by weight of ~~Aloe Vera~~ *Aloe vera* and 95 to 85 % by weight of vegetable oil.
8. (Currently Amended) Transdermal drug delivery system according to claim 1, wherein the matrix comprises the ~~Aloe Vera~~ *Aloe vera*-extract as the only enhancer.

9. (Currently Amended) Transdermal drug delivery system according to claim 1, wherein the matrix comprises 5 to 40, ~~preferably 10 to 35 and especially 15 to 30~~ % by weight of oxybutynin (based on the matrix).

10. (Currently Amended) Transdermal drug delivery system according to claim 1, wherein the matrix comprises 10 to 25, ~~preferably 12 to 20 and especially 14 to 18~~ % by weight of ~~Aloe Vera~~ *Aloe vera*-extract (based on the matrix).

11. (Currently Amended) Transdermal drug delivery system according to claim 1, wherein the matrix comprises 0.1 to 5.0, ~~preferably 0.3 to 3 and especially 0.5 to 2.0~~ % by weight of the crosslinking agent (based on the matrix).

12. (Currently Amended) Transdermal drug delivery system according to claim 1, wherein the system has a surface of 5 to 80, ~~preferably 10 to 60 and especially 20 to 50~~ cm².

13. (New) Transdermal drug delivery system according to claim 9, wherein the matrix comprises 10 to 35 % by weight of oxybutynin (based on the matrix).

14. (New) Transdermal drug delivery system according to claim 13, wherein the matrix comprises 15 to 30 % by weight of oxybutynin (based on the matrix).

15. (New) Transdermal drug delivery system according to claim 10, wherein the matrix comprises 12 to 20 % by weight of *Aloe vera*-extract (based on the matrix).

16. (New) Transdermal drug delivery system according to claim 15, wherein the matrix comprises 14 to 18 % by weight of *Aloe vera*-extract (based on the matrix).

17. (New) Transdermal drug delivery system according to claim 11, wherein the matrix comprises 0.3 to 3 % by weight of the crosslinking agent (based on the matrix).

18. (New) Transdermal drug delivery system according to claim 17, wherein the matrix comprises 0.5 to 2.0 % by weight of the crosslinking agent (based on the matrix).

19. (New) Transdermal drug delivery system according to claim 12, wherein the system has a surface of 10 to 60 cm².

20. (New) Transdermal drug delivery system according to claim 19, wherein the system has a surface of 20 to 50 cm².